about
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best PracticeFocus on renal congestion in heart failureCD74 in Kidney DiseaseCombination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal functionImpaired Vitamin D Signaling in Endothelial Cell Leads to an Enhanced Leukocyte-Endothelium Interplay: Implications for Atherosclerosis DevelopmentHIV and kidney diseases: 35 years of history and consequencesFn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatinA nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injuryHSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by high glucose and angiotensin IITWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21The systemic nature of CKD.Creatinine Clearance Is Not Equal to Glomerular Filtration Rate and Cockcroft-Gault Equation Is Not Equal to CKD-EPI Collaboration Equation.Welcome to the new ckj: an open-access resource integrating clinical, translational and educational research into clinical practice2012 ERA-EDTA Registry Annual Report: cautious optimism on outcomes, concern about persistent inequalities and data black-outs.Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.MXRA5 is a TGF-β1-regulated human protein with anti-inflammatory and anti-fibrotic propertiesIdentification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis.Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation.End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes.Inflammatory Cytokines as Uremic Toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son".Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry RegistryNutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease.Does wealth make health? Cherchez la renal replacement therapy.Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.Start-up of a clinical sample processing, storage and management platform: organisation and development of the REDinREN Biobank.Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells.Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implicationsLaser therapy in metabolic syndrome-related kidney injury.Animal models of cardiovascular diseasesNew paradigms in cell death in human diabetic nephropathy.Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis.Translational nephrology: what translational research is and a bird's-eye view on translational research in nephrologyHealthcare-associated infections: new challenges looking for answers.A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI.Hyperlipidemia-associated renal damage decreases Klotho expression in kidneys from ApoE knockout miceDifferential effects of oral and intravenous l-carnitine on serum lipids: is the microbiota the answer?CKD hotspots around the world: where, why and what the lessons are. A CKJ review series.
P50
Q26767011-0496E504-DF51-4CF9-A801-707324755063Q26769905-4142A3FE-38BC-4CB2-A0AA-FB38DB1B3E62Q26781254-2A827522-16ED-4332-B9AF-E8EDC003954FQ26795398-011C978A-7ABF-4309-BF0E-C391685A9F55Q27320886-F0BFA909-7814-40F3-AA7D-C0914BA9C6D5Q28069641-A7B6CEFD-E805-4EEC-8803-A477741CDF68Q28249401-ED18D2BC-77DF-4667-8617-AA8AC4CF406FQ28475948-B057D166-9028-4D25-86E7-566207984AE7Q28578531-A37CD561-0986-4804-AA0D-199DCA913B55Q28749137-71149D28-E7E2-4C5B-AAC6-9A67C900EB76Q30234695-08D4A942-A696-4988-8C41-57B83BC75E18Q30244202-ED07EF8C-2247-4375-9539-9D0E0F22A658Q30487674-17F3470F-71D5-4316-98B3-7E6F43F86C57Q30963433-AC2F9D7E-A00D-4C6E-AE8C-F89760CF039FQ31120984-31264E33-2D8A-4B03-8F75-35750AD63595Q33112694-8FE97E0E-3733-4B12-92B7-63AC5201161EQ33271663-41B7ACF6-51BF-4D41-AEF9-6F89101BF0E7Q33393631-77D45327-67BD-4AF2-BE5C-E801DB97168CQ33511700-1C946B3B-52B4-4BFD-A49B-B1D61C154246Q33536636-CCD5EFFB-942E-4746-8BEF-68A306620D85Q33611989-B9186137-C0B6-4330-9743-742DF1098CC0Q33683158-A08E70CD-53BA-44FF-92AB-6E76CC673774Q33749467-739B924E-A4D1-4F06-9383-FCDDA124161FQ33793469-4EB61F4B-4602-43E1-9B11-0A80DAC33509Q33985444-4202283D-4254-41B8-AAA2-D8BD50FD8F87Q34147235-E9629708-BE8D-477B-865E-C31B93EF5138Q34245670-1ECE0BBF-9B8A-43F8-A7E7-35EBF2C5F561Q34450860-26112D30-E94E-422E-A875-E65CF6E4F9EBQ34556186-57C1E9C7-BA24-4DEF-91DE-5E900B367909Q34566817-81D64993-9ECA-488C-82EB-3163B1254479Q34591282-5FAD3010-15AF-4665-94FF-55FBE8A1F7ADQ34622431-9E30CB1B-859F-44B4-A681-5AD8F91844E7Q34751855-0AC66D1D-873D-4614-AF1E-F1345EE233F6Q35026202-12851D2F-3910-4913-BEAD-15BC57CA1B20Q35026517-E10320D8-74E9-4D2B-8DB1-83B432502CA0Q35026522-B95D3F22-5D36-4C15-9F2A-F9429ED3716FQ35029014-243AC117-5C86-44A5-9FD0-261415B08D0FQ35080598-7A60687C-2548-41EC-BE61-32EDBAEF7472Q35232161-6068F2C3-422E-4C96-B56C-45A92645FCAAQ35310700-60F63AFE-3836-4CD8-B434-5B6A83708B7B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alberto Ortiz
@ast
Alberto Ortiz
@en
Alberto Ortiz
@es
Alberto Ortiz
@nl
type
label
Alberto Ortiz
@ast
Alberto Ortiz
@en
Alberto Ortiz
@es
Alberto Ortiz
@nl
prefLabel
Alberto Ortiz
@ast
Alberto Ortiz
@en
Alberto Ortiz
@es
Alberto Ortiz
@nl
P106
P1153
7201911399
P21
P31
P496
0000-0002-9805-9523